Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126178 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
A Phase 3 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00126178 is a Phase 3 study that was terminated before completion, run by Agenus. The registered enrollment target is 600 participants.
The verdict
NCT00126178, a Phase 3 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
This is an international, open label, randomized phase 3 trial in which patients with surgically removable kidney cancer will be randomly selected post-operatively to receive adjuvant treatment with autologous HSPPC-96 or no adjuvant treatment. All patients will undergo complete surgical removal of their tumors.
Interventions
- BIOLOGICAL HSPPC-96
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126178
The ClinicalTrials.gov registry entry for NCT00126178 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HSPPC-96 is the first listed.
NCT00126178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126178 about?
NCT00126178 is a clinical study titled "Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer". This is an international, open label, randomized phase 3 trial in which patients with surgically removable kidney cancer will be randomly selected post-operatively to receive adjuvant treatment with autologous HSPPC-96 or no adjuvant treatment. All patients will undergo complete surgical removal of ...
What is the current status of trial NCT00126178?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2005-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00126178?
The interventions under investigation include: HSPPC-96 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00126178?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.